Results 41 to 50 of about 2,874 (159)

Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy

Pharmaceutics, 2023
Outpatient parenteral antimicrobial therapy (OPAT) is a useful treatment strategy against Pseudomonas aeruginosa and other multidrug-resistant bacteria.
Beatriz Fernández-Rubio, Laura Herrera-Hidalgo, Arístides de Alarcón, Rafael Luque-Márquez, Luis E. López-Cortés, Sònia Luque, José María Gutiérrez-Urbón, Aurora Fernández-Polo, Alicia Gutiérrez-Valencia, María V. Gil-Navarro   +9 more
doaj   +1 more source

Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem‐resistant Enterobacteriaceae [PDF]

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
Vaborbactam (VAB; formerly RPX7009) is a novel beta‐lactamase inhibitor based on a cyclic boronic acid pharmacophore with potent inhibitory activity against Ambler class A and C beta‐lactamases. It has been co‐formulated with meropenem to restore its activity against Klebsiella pneumoniae carbapenemases (KPC).
Sarah Christina Jane Jorgensen, Michael Joseph Rybak   +1 more
openaire   +2 more sources

Mechanistic basis for inhibition of the extended‐spectrum β‐lactamase GES‐1 by enmetazobactam and tazobactam

FEBS Letters, Volume 599, Issue 22, Page 3284-3300, November 2025.
Antimicrobial resistance (AMR) is of huge importance, resulting in over 1 million deaths each year. Here, we describe how a new drug, enmetazobactam, designed to help fight resistant bacterial diseases, inhibits a key enzyme (GES‐1) responsible for AMR. Our data show it is a more potent inhibitor than the related tazobactam, with high‐level computation
Michael Beer, Philip Hinchliffe, Marko Hanževački, Christopher R. Bethel, Catherine L. Tooke, Marc W. Van der Kamp, Krisztina M. Papp‐Wallace, Robert A. Bonomo, Stuart Shapiro, Adrian J. Mulholland, James Spencer   +10 more
wiley   +1 more source

Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae: A Retrospective Case Series and Literature Review

Antibiotics, 2022
Objectives: The aim of this study was to describe our experience of a combination treatment including meropenem/vaborbactam (M/V) plus aztreonam (ATM) for bloodstream infections (BSIs) due to ceftazidime/avibactam-resistant Klebsiella pneumoniae (CAZ/AVI-
Alessandra Belati, Davide Fiore Bavaro, Lucia Diella, Nicolò De Gennaro, Francesco Di Gennaro, Annalisa Saracino   +5 more
doaj   +1 more source

Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying blaKPC Collected Worldwide [PDF]

Open Forum Infectious Diseases, 2017
Abstract Background Meropenem-vaborbactam (MER-VAB) is a carbapenem-β-lactamase inhibitor combination with enhanced activity against KPC-producing Enterobacteriaceae recently evaluated in a phase 3 clinical trials for cUTIs and infections due to CRE.
Castanheira, Mariana, Mendes, Rodrigo E, Duncan, Leonard R, Woosley, Leah N, Flamm, Robert K   +4 more
openaire   +1 more source

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Infectious Diseases and Therapy, 2018
Introduction Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations.
Richard G. Wunderink, Evangelos J. Giamarellos-Bourboulis, Galia Rahav, Amy J. Mathers, Matteo Bassetti, Jose Vazquez, Oliver A. Cornely, Joseph Solomkin, Tanaya Bhowmick, Jihad Bishara, George L. Daikos, Tim Felton, Maria Jose Lopez Furst, Eun Jeong Kwak, Francesco Menichetti, Ilana Oren, Elizabeth L. Alexander, David Griffith, Olga Lomovskaya, Jeffery Loutit, Shu Zhang, Michael N. Dudley, Keith S. Kaye   +22 more
doaj   +1 more source

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae

Infection and Drug Resistance, 2018
Lindsay A Petty,1 Oryan Henig,1 Twisha S Patel,2 Jason M Pogue,3 Keith S Kaye1 1Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA; 2Department of Pharmacy Services, University of ...
Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS   +4 more
doaj  

Genomic analysis and antimicrobial activity of β-lactam/β-lactamase inhibitors and other agents against KPC-producing Klebsiella pneumoniae clinical isolates from Brazilian hospitals

Scientific Reports, 2023
Carbapenem-resistant Klebsiella pneumoniae (CRKP) are highly disseminated worldwide, and isolates co-resistant to other antimicrobial agents pose a threat to effective antimicrobial therapy. Therefore, evaluation of novel antimicrobial drugs is needed to
Carlos Henrique Camargo, Amanda Yaeko Yamada, Andreia Rodrigues de Souza, Marcos Paulo Vieira Cunha, Pedro Smith Pereira Ferraro, Claudio Tavares Sacchi, Marlon Benedito dos Santos, Karoline Rodrigues Campos, Monique Ribeiro Tiba-Casas, Maristela Pinheiro Freire, Pasqual Barretti   +10 more
doaj   +1 more source

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing

Pharmaceuticals
Antimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam.
Małgorzata Brauncajs, Filip Bielec, Marlena Malinowska, Dorota Pastuszak-Lewandoska   +3 more
doaj   +1 more source